Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, J. E.
(Chest. 2004;126:668-670.)
© 2004 American College of Chest Physicians

Which Exercise Test Should Be Used for Patients With Symptomatic COPD?

James E. Johnson, MD, FCCP

Birmingham, AL
Dr. Johnson is Associate Professor of Medicine, Physiology and Biophysics, Division of Pulmonary, Allergy and Critical, Care Medicine, University of Alabama at Birmingham.

Correspondence to: James E. Johnson, MD, FCCP, BDB 398, 1808 Seventh Ave South, Birmingham, AL 35294-0012; e-mail: jej{at}uab.edu

Over the past decade, our understanding of exercise pathophysiology in patients with chronic airflow obstruction has expanded rapidly. Several articles, including one in this issue of CHEST by Turner et al (see page 765), have explored the responses to various testing protocols. I will argue that the 6-min walk test (6MWT) is the best one to use at a single point in time to assess a patient with symptomatic airflow limitation. It is also a good test to repeat to document declining exercise tolerance, and an adequate test to document improvement in function. Treadmill testing at constant workload is more sensitive for the latter purpose.1 Treadmill testing is also better if more advanced monitoring such as continuous electrocardiography or expired gas analysis is required during exercise. Cycle ergometry is less desirable since it has been shown to have important respiratory differences when compared with walking in this group, and is less closely related to the patient’s usual activities.2

Why should exercise testing be done in patients with COPD? The main reason is that it allows objective assessment of the effect of the disease on the patient’s ability to function. Such information may be helpful in deciding how aggressively to treat underlying airflow obstruction as well as in determining the need for supplemental oxygen, pulmonary rehabilitation, and surgical therapy (lung volume reduction and transplantation). Also, functional capability is an independent predictor of various outcomes in this group. Both mortality34 and postoperative complications56 are inversely related to this important variable. Unfortunately, spirometric parameters are poorly predictive of exercise ability,7 such that one patient may be in a wheelchair and another living independently with the same reduction in FEV1. Functional capability is often determined by patient history, but exercise testing provides a more objective assessment.

The advantages of the 6MWT are that it is involves a simple and safe activity that is familiar to the patient. It requires nothing other than a 100-foot hallway, and it has become better standardized with normal reference equations and American Thoracic Society guidelines8 aimed at reducing some of the sources of variability. This test represents an improvement over the older 12-min version that was more difficult for patients to complete.

For most normal subjects, especially younger ones, the 6MWT is a submaximal exercise test since running is not allowed. However, for patients with severe COPD, it produces stress similar to a maximal test. In the present study, the 6MWT was compared to two other incremental maximal tests, one walking and one on the bicycle, in a group of patients with COPD and severe airflow obstruction (mean FEV1 28.9% of predicted). They reached similar heart rates and dyspnea scores in all three tests, and both walking test results demonstrated greater arterial oxygen desaturation than did the cycle ergometry test. The patients’ Borg scores rose linearly throughout the time they performed the 6MWT.

One would expect a normal subject to have minimal dyspnea with brisk walking, and one might expect a patient with COPD to have his or her dyspnea level rise to some point and then reach a plateau, but this did not happen. A study by O’Donnell et al9 may explain this finding. Patients with severe COPD (mean FEV1 40% of predicted) were exercised on a treadmill at a constant submaximal workload, a situation similar though not exactly like the 6MWT (where patients may vary their speed). The investigators documented a progressive decline in inspiratory capacity (presumably due to hyperinflation) and a linear rise in Borg score. The progressively worsening respiratory mechanical stress eventually caused the patients to stop with an average Borg score of approximately 5 ("severe dyspnea"). The mechanism of the worsening dyspnea despite the relatively constant workload in the present study during the 6MWT is likely to be the same.

The main disadvantage of the 6MWT is that it only measures global function, without specific information regarding the cause of the limitation. Also, patients with minimal or mild limitation from their disease cannot fully demonstrate their exercise ability since walking on a level surface is the only activity allowed. Another disadvantage is that a patient can only show improvement in ability in subsequent testing by walking faster. Some patients have difficulty walking faster due to such factors as stride length, but can walk up a steeper grade with improvement in their overall condition.10 A treadmill allows this option whereas floor walking tests do not. Also, both rehabilitation and medications are more likely to make patients with COPD able to walk longer at the same speed, rather than faster.19 Timed walk tests, by definition, cannot be used to demonstrate this, but a treadmill set at a constant speed can. Overall, the treadmill is more versatile and can be used with or without expired gas analysis, but is more expensive and requires space and expertise.

The incremental shuttle walking test (ISWT) is intended to be a maximal exercise evaluation but has little advantage in this group of patients. It has all the disadvantages of the 6MWT in that patients can only demonstrate improvement by walking faster. Also, it is more complicated and therefore likely to have greater variability in the results. Since the patient starts out at slower speeds, dyspnea scores and heart rate rise more gradually than the 6MWT as noted in the present study. The slower rise in heart rate may be an advantage for a patient who has coronary disease; however, one could argue that if this is likely, the patient should be exercised on a treadmill with ECG monitoring. A newer version of this test referred to as the endurance shuttle walking test can be used to show increases in walking time.11 It requires that the patient first do an ISWT, and then subsequent tests measure the distance walked at 85% of the maximum speed along the same 10-m shuttle course. This may serve as an alternative to constant rate submaximal treadmill testing as a sensitive means of following improvement in exercise function, but further research is needed.

Finally, stationary bicycle exercise should be considered. It has the advantage of very precise quantitation of external work, which can facilitate calculation of certain parameters during formal cardiopulmonary exercise testing. Also, the patient is in a more fixed position than when on a treadmill, so that becoming disconnected from gas measurement equipment is less of a problem. The main disadvantage is that cycling has different physiologic effects compared with walking in patients with severe COPD. In a study by Palange et al,2 nine patients with severe COPD underwent ISWT and bicycle ergometry. Portable equipment allowed expired gas analysis via face mask with both tests. At peak exercise, heart rate, oxygen consumption, expired ventilation, dyspnea, and leg effort scores were similar with both types of exertion; however, PaO2 was substantially higher with cycling (65.0 torr vs 57.7 torr). Also, carbon dioxide production was about 31% higher with cycling, and the blood lactate level was higher and the peak minute ventilation/CO2 and physiologic dead space ventilation were lower than with walking. The authors speculated that differences in body posture, functional residual capacity, and/or hemodynamics probably caused these findings. The ability to fix the arm position with the handlebars may improve accessory muscle use in a manner that improves respiratory efficiency on the bicycle. The authors concluded that "cycling may not reflect precisely their ventilatory and metabolic requirements for daily activities such as walking."

The current study and another recent investigation12 confirm that arterial desaturation is more likely to occur with the 6MWT than with maximal cycling. Whether walking or cycling more correctly demonstrates the physiologic abnormalities with exercise in severe COPD really does not matter. Most patients with COPD do not ride a bicycle, but they nearly all walk.

In summary, Turner et al have added to our understanding of the evaluation of dyspneic COPD patients by comparing the 6MWT, ISWT, and cycle ergometry tests in a group with substantial airflow obstruction. In this population, all three act as maximal tests. The walking tests are more likely to identify oxygen desaturation, and the 6MWT is the easiest to perform. For many situations, it is an adequate test, although treadmill testing may be necessary for specific applications such as those mentioned above.

Footnotes

Dr. Johnson has received honoraria for speaking for Boehringer Ingleheim and Glaxo Pharmaceutical Companies.

References

  1. Pulmonary rehabilitation–1999: official statement of the American Thoracic Society. Am J Respir Crit Care Med 1999;159,1566-1582
  2. Palange, P, Forte, S, Onorati, P, et al Ventilatory and metabolic adaptations to walking and cycling in patients with COPD. J Appl Physiol 2000;88,1715-1720[Abstract/Free Full Text]
  3. Anthonisen, NR Prognosis in chronic obstructive pulmonary disease: results from multicenter clinical trials. Am Rev Respir Dis 1989;140,S95-S99[ISI][Medline]
  4. Oga, T, Nishimura, K, Tsukino, M, et al Analysis of the factors related to mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167,544-549[Abstract/Free Full Text]
  5. Arozullah, AM, Khuri, SF, Henderson, WG, et al Development and validation of a multifactorial risk index for predicting postoperative pneumonia after major noncardiac surgery. Ann Intern Med 2001;135,847-857[Abstract/Free Full Text]
  6. Datta, D, Lahiri, B Preoperative evaluation of patients undergoing lung resection surgery. Chest 2003;123,2096-2103[Abstract/Free Full Text]
  7. Solway, S, Brooks, D, Lacasse, Y, et al A qualitative systemic overview of the measurement properties functional walk tests used in the cardiorespiratory domain. Chest 2001;119,256-270[Abstract/Free Full Text]
  8. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166,111-117[Free Full Text]
  9. O’Donnell, DE, Lam, M, Webb, KA Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158,1557-1565[Abstract/Free Full Text]
  10. Johnson, JE, Gavin, DJ, Adams-Dramiga, S Effect of training with heliox and noninvasive positive pressure ventilation on exercise ability in patients with severe COPD. Chest 2002;122,464-472[Abstract/Free Full Text]
  11. Revill, SM, Morgan, MDL, Singh, SJ, et al The endurance shuttle walk: a new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease. Thorax 1999;54,213-222[Abstract/Free Full Text]
  12. Poulain, M, Durand, F, Palomba, B, et al 6-minute walk testing is more sensitive than maximal incremental cycle testing for detecting oxygen desaturation in patients with COPD. Chest 2003;123,1401-1407[Abstract/Free Full Text]




This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, J. E.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS